UBS raised the firm’s price target on Veracyte (VCYT) to $46 from $43 and keeps a Buy rating on the shares post the earnings report.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.